Basic Information
Celldemic
Regulatory Information
EMEA/H/C/006052
April 19, 2024
February 22, 2024
1
January 29, 2025
Company Information
the netherlands
Paasheuvelweg 28 1105 BJ Amsterdam
Seqirus Netherlands B.V.
Drug Classification
Active Substances Detail
Influenza virus A/turkey/Turkey/1/2005 (H5N1) NIBRG-23 strain, HA surface antigen
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Celldemic is indicated for active immunisation against H5N1 subtype of Influenza A virus in adults and infants from 6 months of age and above. Celldemic should be used in accordance with official recommendations.
Overview Summary
Celldemic is a vaccine used to protect adults and children from 6 months of age against influenza (flu) caused by the H5N1 subtype of the influenza A virus (sometimes called ‘bird flu’ or ‘avian flu’). Celldemic contains small amounts of proteins from an H5N1 strain of the influenza A virus. The virus has been inactivated so that it does not cause any disease in people who receive the vaccine.